Highlights

  • Biome Australia (ASX:BIO) reported record FY26 sales Revenue of A$23.9 million.
  • The company achieved positive underlying EBITDA during FY26.
  • Activated Probiotics continued gaining traction across Australian pharmacy channels.
  • International expansion and onshore Manufacturing remain key growth initiatives.

Biome Australia (ASX:BIO) continues progressing towards a profitable growth model after reporting record FY26 sales and positive underlying earnings. The company’s shares were trading at AUD 0.27, unchanged on 21 August 2026.

The company’s latest results highlighted stronger consumer demand, increased pharmacy penetration and progress in building a scalable probiotics platform.

For investors assessing Biome Australia (ASX:BIO), the key areas of focus remain revenue growth, profitability sustainability, pharmacy Market Share and international expansion.

What is happening with Biome Australia?

Biome Australia develops and markets probiotic and microbiome health products, with its Activated Probiotics range representing the core of its business.

The company has focused on expanding distribution through community pharmacies while improving Brand Recognition and consumer demand.

FY26 represented an important stage in the company’s development, with growth beginning to translate into positive underlying earnings.

Latest company developments

Biome Australia reported FY26 sales revenue of A$23.9 million, representing approximately 30% growth compared with the previous year.

The June half contributed approximately A$11.5 million in sales, increasing 20% year on year.

The Activated Probiotics range remained the primary growth driver, with Biome Daily identified as the leading probiotic product by units sold in Australia.

The broader Activated Probiotics brand has also grown into one of the top three probiotic brands within the Australian community pharmacy sector.

Same-store sales across Australian channels increased 39%, while June marked the first month where sell-through exceeded 100,000 units.

International sales increased 26% to A$1.8 million, supported by distribution across Canada, Ireland, the United Kingdom and New Zealand.

The company also entered into a binding agreement with Specialty Probiotics Australia for onshore manufacturing, with the first commercial batch targeted for September 2026.

The manufacturing arrangement requires no upfront Capital Investment and is designed to improve Supply security and support future operational efficiency.

What do the numbers say?

Biome Australia’s FY26 performance highlighted a shift from growth investment towards Earnings generation.

Revenue growth of approximately 30% was supported by increased consumer demand, stronger pharmacy relationships and improved product sales.

The company’s move to positive underlying EBITDA represents an important milestone, showing progress towards converting revenue growth into profitability.

Same-store sales growth of 39% provides evidence of increasing Demand within existing channels rather than relying only on distribution expansion.

The milestone of more than 100,000 units sold through in June highlights improving product velocity and customer adoption.

International revenue remains relatively small at A$1.8 million, meaning Australian pharmacy channels remain the primary earnings driver.

The onshore manufacturing agreement may provide future Margin benefits, although the impact will depend on successful implementation and production scaling.

What could drive the shares from here?

Continued growth across Australian pharmacy channels remains a key potential driver for Biome Australia (ASX:BIO).

Maintaining same-store growth, increasing market share and sustaining positive earnings would strengthen the company’s profitable-growth narrative.

The transition to onshore manufacturing could support supply-chain efficiency and potentially improve margins as production scales.

International expansion across Canada, Ireland, the United Kingdom and New Zealand provides additional growth opportunities from a relatively small base.

Further product launches and increased adoption of the Activated Probiotics range could support continued revenue expansion.

Risks investors should watch

Biome operates in the competitive probiotics and supplements sector, where larger brands and established healthcare companies compete for consumer attention.

The company remains heavily exposed to Australian pharmacy channels, meaning changes in distribution relationships or competitive dynamics could affect performance.

International operations are still developing and may require additional investment in marketing, distribution and regulatory compliance.

The manufacturing transition introduces execution risks as production arrangements change.

Positive EBITDA is a recent achievement, meaning the company must demonstrate that profitability can be maintained over multiple reporting periods.

As a small-cap healthcare company, Biome Australia may also experience higher share price volatility.

Investor takeaway

Biome Australia (ASX:BIO) has moved towards a profitable-growth phase after delivering record FY26 sales, stronger pharmacy penetration and positive underlying EBITDA.

The company’s growth strategy is supported by consumer demand for probiotics, expanding brand recognition and early international opportunities.

The key factors ahead include sustaining EBITDA growth, maintaining pharmacy momentum, successfully implementing onshore manufacturing and expanding international sales.